Mazyar Shadman MD MPH

Hematologic Oncology

Associate Professor of Medicine - Medical Oncology - University of Washington Associate Professor, Clinical Research Division, Fred Hutchinson Cancer Research Center

Join to View Full Profile

825 Eastlake Ave ESeattle, WA 98109
Phone+1 206-606-1000
Fax+1 206-606-1025

Education & Training

University of WashingtonFellowship, Hematology and Medical Oncology, 2011 - 2014
Cleveland Clinic FoundationResidency, Internal Medicine, 2008 - 2011
University of WashingtonMPH, Cancer Epidemiology , 2006 - 2008
Tehran University of Medical Sciences School of MedicineClass of 2004

Certifications & Licensure

WA State Medical License 2011 - 2025
OH State Medical License 2008 - 2011
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Trainee Research Award American Society of Hematology (ASH)

Clinical Trials

Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission Start of enrollment: 2007 Feb 01
Completed
Phase 2
Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2009 Jun 01
Completed
Phase 1, Phase 2
Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes Start of enrollment: 2013 May 01
Completed
Not Applicable
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2014 Mar 10
ACTIVE_NOT_RECRUITING
PHASE3
HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection Start of enrollment: 2016 Aug 15
Withdrawn
Phase 1
A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Start of enrollment: 2015 Jul 27
Completed
Phase 1, Phase 2
A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2015 Sep 15
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation Start of enrollment: 2015 Sep 18
Completed
Phase 1
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma Start of enrollment: 2018 Jan 23
ACTIVE_NOT_RECRUITING
PHASE2
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas Start of enrollment: 2017 Dec 05
Active, not recruiting
Phase 1, Phase 2
Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia Start of enrollment: 2019 Feb 12
ACTIVE_NOT_RECRUITING
PHASE3
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study Start of enrollment: 2021 Mar 02
RECRUITING
PHASE3
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-y...
Andrew J Portuguese, Jennifer J Huang, Yein Jeon, Mahnoosh Taheri, Aya Albittar
Haematologica. 2025-03-13
Consensus in CLL: global needs matter.
Mazyar Shadman, Bita Fakhri, Nitin Jain
Blood Advances. 2025-03-11
Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQ...
Mazyar Shadman, Talha Munir, Tadeusz Robak, Jennifer R Brown, Brad S Kahl
Journal of Clinical Oncology. 2025-03-01

Journal Articles

Translating Anti-CD19 CAR T-cell Therapy into Clinical Practice for relapsed/refractory Diffuse Large B-cell Lymphoma
Mazyar Shadman, Ajay K Gopal, Victor A Chow, Blood

Abstracts/Posters

Low Achievement of End of Life Quality Measures in Large B-Cell Lymphoma Patients Who Progressed after CD19-Specific CAR-T Cell Therapy
Mazyar Shadman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
High Rate of Exclusion of HIV Infected Patients from Modern Lymphoma Studies: An Analysis of Current United States Therapeutic Trials
Mazyar Shadman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Resu...
Mazyar Shadman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies
Mazyar Shadman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Impact of Lab Abnormalities at the Time of Progression in Patients Receiving CD19-Specific CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphomas
Mazyar Shadman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible BrutonÍS Tyrosine Kinase Inhibitor, Vecabrutinib, ...
Mazyar Shadman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Treatment Outcomes with Purine Nucleoside Analog Alone or with Rituximab for Hairy Cell Leukemia Patients at First Relapse: A Multi-Center Outcomes Analysis
Mazyar Shadman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies
Mazyar Shadman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Phase II, Multicenter Study of High Dose Chemotherapy with Autologous Stem Cell Transplant Followed By Maintenance Therapy with Romidepsin for T-Cell Lymphoma
Mazyar Shadman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Veneto-STOP Study: Sequential Assessment of Minimal Residual Disease By Next Generation Sequencing to Optimize Outcomes and Minimize Exposure in Venetoclax-Treated CLL...
Mazyar Shadman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Veneto-STOP Study: Sequential Assessment of Minimal Residual Disease By Next Generation Sequencing to Optimize Outcomes and Minimize Exposure in Venetoclax-Treated CLL...
Mazyar Shadman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Factors Associated with Response, CAR-T Cell In Vivo Expansion, and Progression-Free Survival after Repeat Infusions of CD19 CAR-T CellsClinically Relevant Abstract
Mazyar Shadman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies
Mazyar Shadman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Novel Comorbidity Score Derived from a Large Multicenter Retrospective Cohort Study of Patients Treated ...
Mazyar Shadman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Toxicities and Outcomes of Acalabrutinib-Treated Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis of Real World Patients
Mazyar Shadman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

CD20 Targeted CAR-T for High-Risk B-Cell Non-Hodgkin Lymphomas
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Relapsed or Refractory CLL after CD19-Specific CAR-T Therapy: Treatment Patterns and Clinical Outcomes
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Efficacy and Toxicity of JCAR014 in Combination with Durvalumab for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Chronic Lymphocytic Leukemia (CLL) Transformed into Hodgkin Lymphoma (HL): Clinical Characteristics and Outcomes from a Large Multi-Center Collaboration
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Factors Impacting Progression-Free Survival after CD19-Specific CAR-T Cell Therapy for Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Outcomes of Patients with Large B-Cell Lymphomas and Progressive Disease Following CD19-Specific CAR T-Cell TherapyClinically Relevant Abstract
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Pembrolizumab in Combination with Standard RCHOP Therapy for Previously Untreated Diffuse Large B-Cell Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B-Cell Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Press Mentions

BeiGene Advances Leadership in CLL at ASH 2024 with New Data from Its Hematology Franchise Including BRUKINSA® and Novel Pipeline AssetsDecember 9th, 2024
Tip Sheet: BRCA Cancer Risks for Men, a New Way to Classify Brain Tumors, Funding for Bile Duct Cancer — and Cancer Care in LGBTQ+ CommunitiesAugust 7th, 2024
High CLL Therapy Cessation Rates in Real World PracticeApril 17th, 2023
Join now to see all